Fig. 3: IRF3 suppresses the CRC via inhibiting Wnt signaling.
From: IRF3 prevents colorectal tumorigenesis via inhibiting the nuclear translocation of β-catenin
a The signal pathways were enriched with the 65 genes that upregulated in tumor tissue only in “KO” from the RNA-seq analysis results. b Immunofluorescence analysis of β-catenin nuclear translocation in colorectal tumors from IRF3+/+ and IRF3−/− mice after treatment with AOM/DSS (days 0 and 90). Scale bar, 20 μm. c, d Real time qPCR analysis for expression of the Wnt target, and associated genes in the distal colon and tumors from IRF3fl/fl and IRF3fl/flVillincre (day 0, n = 3 mice/group; day 15, n = 4 mice/group; day 90, n = 7 mice/group) mice. e–f Images (e) and quantifications (f) of the number (left) and size (right) of organoids from IRF3+/+ and IRF3−/− colon stem cells. g Representative images of colon tumors from IRF3fl/fl and IRF3fl/flVillincre mice on day 90 after AOM/DSS model with pbs or ICG-001 treatment. h–j Colon tumors counts, size, and tumor load in AOM/DSS-treated mice with PBS or ICG-001 treatment (300 mg/kg per day, orally, once daily, six times 1 week for the last 10 weeks of the AOM/DSS model; PBS group, n = 6 mice/group; ICG-001 group, n = 7 mice/group). k Representative MRI images of IRF3fl/fl and IRF3fl/flVillincre mice with PBS or ICG-001 treatment (300 mg/kg per day, orally, once daily, six times 1 week for the last 10 weeks of the AOM/DSS model). Arrowhead indicates colon tumor. Each symbol represents one organoid (e) or an individual mouse (c, d, h–j). *P < 0.05; **P < 0.01; ***P < 0.001; NS not statistically significant by two-tailed t test (c–f, h–j). Data represent two (b–d, g–k) or three independent experiments (e, f), and are presented as mean ± s.e.m. in a–j. See also Supplementary Fig. S3.
